Last reviewed · How we verify
Intranasal calcitonin
Intranasal calcitonin is a peptide hormone that binds to calcitonin receptors on osteoclasts to inhibit bone resorption and increase bone mineral density.
Intranasal calcitonin is a peptide hormone that binds to calcitonin receptors on osteoclasts to inhibit bone resorption and increase bone mineral density. Used for Osteoporosis in postmenopausal women, Paget's disease of bone, Hypercalcemia of malignancy.
At a glance
| Generic name | Intranasal calcitonin |
|---|---|
| Also known as | Miacalcin and Miacalcic |
| Sponsor | Université de Montréal |
| Drug class | Calcitonin receptor agonist |
| Target | Calcitonin receptor |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Bone metabolism |
| Phase | FDA-approved |
Mechanism of action
Calcitonin is a 32-amino acid peptide hormone that acts on calcitonin receptors present on osteoclasts and other bone cells. By binding to these receptors, it directly inhibits osteoclast activity and promotes osteoclast apoptosis, thereby reducing bone resorption. The intranasal formulation allows systemic absorption of the peptide to achieve therapeutic effects on bone metabolism.
Approved indications
- Osteoporosis in postmenopausal women
- Paget's disease of bone
- Hypercalcemia of malignancy
Common side effects
- Nasal irritation or rhinitis
- Nausea
- Flushing
- Headache
- Hypocalcemia
Key clinical trials
- The Use of Intranasal Calcitonin to Improve Pain and Activity in Elderly Pelvic Ring Injuries (PHASE4)
- Calcitonin in the Treatment of Fibromyalgia (PHASE4)
- A Study Comparing Oral Calcitonin to Nasal Spray Calcitonin in Postmenopausal Osteoporotic Women (PHASE3)
- A Dose Selection Study of Oral Recombinant Salmon Calcitonin (rsCT) in Normal, Healthy, Postmenopausal Women (PHASE2)
- A Study for Patients With Osteoporosis (PHASE3)
- Analgesic Effect of Intranasal Calcitonin on Patients With Fractured Ribs (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intranasal calcitonin CI brief — competitive landscape report
- Intranasal calcitonin updates RSS · CI watch RSS
- Université de Montréal portfolio CI